Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1535-1539

  Kolostova, Katarina ^a   Pinterova, Daniela ^a   Hoffman, Robert M ^b,c   Bobek, Vladimir ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ANTICANCER INC   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Circulating cancer cells; Culture; Fluorescence; GFP; Imaging; Immunomagnetic beads; Isolation; Orthotopic; PC 3; Prostate cancer

Indexed keywords

ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; GREEN FLUORESCENT PROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL ISOLATION; CELL STRUCTURE; CELL VIABILITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIAPHRAGM; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOMAGNETIC BEAD; IMMUNOMAGNETIC SEPARATION; LYMPH NODE METASTASIS; MALE; MATERIAL COATING; MOUSE; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; GLUTAMATE CARBOXYPEPTIDASE II; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79958115672     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M and Hoffman RM: Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res, Epub, 2010. DOI: 10.1016/j.jss.2010.05.007.
2. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R and Kasimir-Bauer S: Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115: 581-590, 2009.
3. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E and Uhr J: Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9: R74, 2007.
4. Morgan TM, Lange PH and Vessella RL: Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12: 3000-3009, 2007.
5. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG and Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65: 713-718, 2005. (Pubitemid 40523005)
6. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M and Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053-7058, 2007. (Pubitemid 350276887)
7. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW and Small EJ: Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99: 519-524, 2007. (Pubitemid 46238821)
8. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309, 2008.
9. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, Groskopf J, Rittenhouse HG, Vessella RL and Reynolds MA: Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 9: 174, 2010.
10. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and Terstappen LW: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12: 4218-4224, 2006.
11. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M and Haber DA: Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359: 366-377, 2008.
12. Heizer KT, Barnes HE, Day L, Harvey J, Billings PR and Forsyth A: Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res 69: 7860-7866, 2009.
13. Glinskii AB, Smith BA, Jiang P, Li X-M, Yang M, Hoffman RM and Glinsky GV: Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models. Cancer Res 63: 4239-4243, 2003. (Pubitemid 36917952)
14. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM and Glinsky GV: Essential role for activation of the Polycomb Group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5: 1886-1901, 2006.
15. Carpenter G and Red-Brewer M: EpCAM: Another surface-to-nucleus missile. Cancer Cell 15: 165-166, 2009.
16. Schindlbeck C, Stellwagen J, Jeschke U, Karsten U, Rack B, Janni W, Jückstock J, Tulusan A, Sommer H and Friese K: Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis 25: 233-240, 2008.
17. Yang M, Jiang P, Sun F-X, Hasegawa S, Baranov E, Chishima T, Shimada H, Moossa AR and Hoffman RM: A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 59: 781-786, 1999. (Pubitemid 29086726)
18. Glinsky GV and Glinsky VV: Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 101: 43-51, 1996. (Pubitemid 26060191)
19. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G and Metcalf JB: Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56: 5319-5324, 1996. (Pubitemid 27011355)
20. Glinsky GV, Glinsky VV, Ivanova AB and Hueser CJ: Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115: 185-193, 1997. (Pubitemid 27196604)
21. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
22. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H, Kyo S, Mizuguchi H, Urata Y, Tanaka N and Fujiwara T: A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 119: 3172-3181, 2009.